FDA has approved TAZVERIK from Epizyme for multiple indications.
The first-in-class EZH2 inhibitor is now indicated for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
The drug is also indicated for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Finally, the agency has approved Tazverik’s use for patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Filed Under: Oncology